Published in J Cancer on April 09, 2012
Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC) | NCT00823290
Sorafenib inhibits epithelial-mesenchymal transition through an epigenetic-based mechanism in human lung epithelial cells. PLoS One (2013) 0.95
Profile of panobinostat and its potential for treatment in solid tumors: an update. Onco Targets Ther (2013) 0.92
Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines. BMC Cancer (2012) 0.88
Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol (2015) 0.87
Endoplasmic reticulum stress plays a pivotal role in cell death mediated by the pan-deacetylase inhibitor panobinostat in human hepatocellular cancer cells. Transl Oncol (2013) 0.85
A Systematic Review of Metastatic Hepatocellular Carcinoma to the Spine. World Neurosurg (2016) 0.77
Quantification of dynamic contrast-enhanced ultrasound in HCC: prediction of response to a new combination therapy of sorafenib and panobinostat in advanced hepatocellular carcinoma. BMJ Case Rep (2012) 0.75
Minnelide, a novel drug for pancreatic and liver cancer. Pancreatology (2015) 0.75
Functions of endothelin-1 in apoptosis and migration in hepatocellular carcinoma. Exp Ther Med (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res (2006) 6.66
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
Histone deacetylase inhibitors in cancer therapy. J Clin Oncol (2009) 4.58
Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol (2008) 3.56
Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett (2009) 2.28
Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol (2007) 2.20
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res (2011) 2.13
Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology (2008) 2.11
Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol (2006) 1.95
Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy (2011) 1.81
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res (2006) 1.81
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res (2008) 1.55
Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett (2008) 1.53
Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol (2009) 1.47
Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res (2010) 1.43
The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res (2011) 1.34
Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther (2010) 1.31
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol Pharmacol (2009) 1.29
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol (2012) 1.26
The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol (2002) 1.25
Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist (2009) 1.14
Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer (2008) 1.12
Apoptosis-modulating drugs for improved cancer therapy. Eur Surg Res (2012) 1.12
HDAC inhibitors and cancer therapy. Prog Drug Res (2011) 1.11
The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood (2012) 1.09
Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors. IDrugs (2007) 1.09
Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int J Mol Med (2009) 1.06
The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. Cell Oncol (2010) 1.04
Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. Int J Oncol (2010) 1.01
Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog (2012) 1.00
MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells. Int J Oncol (2009) 0.99
Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol (2010) 0.98
Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch (2011) 0.97
New drugs, old fashioned ways: ER stress induced cell death. Curr Pharm Biotechnol (2012) 0.91
Deacetylase inhibitors - focus on non-histone targets and effects. World J Biol Chem (2010) 0.90
The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol (2005) 0.90
The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines. Oncol Rep (2008) 0.86
Biomarkers for novel targeted therapies of hepatocellular carcinoma. Histol Histopathol (2009) 0.80
The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response. Hepatology (2010) 2.52
Inhibition of heme oxygenase 1 expression by small interfering RNA decreases orthotopic tumor growth in livers of mice. Int J Cancer (2008) 1.68
Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity (2013) 1.67
Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res (2003) 1.33
The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol (2002) 1.25
Hepatic angiomyolipoma: a series of six cases with emphasis on pathological-radiological correlations and unusual variants diagnosed by core needle biopsy. Int J Clin Exp Pathol (2012) 1.21
Reactive oxygen species mediate thymoquinone-induced apoptosis and activate ERK and JNK signaling. Apoptosis (2010) 1.21
Radiofrequency thermal ablation of liver tumors. Eur Radiol (2005) 1.11
Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells. Cancer Res (2008) 1.11
Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models. J Cell Mol Med (2008) 1.10
Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors. IDrugs (2007) 1.09
Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models. Scand J Gastroenterol (2007) 1.08
Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol (2006) 1.04
The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. Cell Oncol (2010) 1.04
Labeling and glycosylation of peptides using click chemistry: a general approach to (18)F-glycopeptides as effective imaging probes for positron emission tomography. Angew Chem Int Ed Engl (2010) 1.03
GBP-1 acts as a tumor suppressor in colorectal cancer cells. Carcinogenesis (2012) 1.01
Doppler measurements: a surrogate marker of liver fibrosis? Eur J Gastroenterol Hepatol (2002) 1.01
Dual anticancer activity in a single compound: visible-light-induced apoptosis by an antiangiogenic iridium complex. Chem Commun (Camb) (2011) 0.97
Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch (2011) 0.97
Overview of major classes of plant-derived anticancer drugs. Int J Biomed Sci (2009) 0.96
bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells. J Cell Mol Med (2007) 0.95
Active Wnt signalling is associated with low differentiation and high proliferation in human biliary tract cancer in vitro and in vivo and is sensitive to pharmacological inhibition. Int J Oncol (2010) 0.94
PIM1 kinase as a target for cancer therapy. Expert Opin Investig Drugs (2012) 0.93
Rhenium complexes with visible-light-induced anticancer activity. ChemMedChem (2013) 0.92
The expression pattern of PDX-1, SHH, Patched and Gli-1 is associated with pathological and clinical features in human pancreatic cancer. Pancreatology (2008) 0.92
New drugs, old fashioned ways: ER stress induced cell death. Curr Pharm Biotechnol (2012) 0.91
Percutaneous US-guided radiofrequency ablation with perfused needle applicators: improved survival with the VX2 tumor model in rabbits. Radiology (2003) 0.91
Current status of therapeutic targeting of developmental signalling pathways in oncology. Curr Pharm Biotechnol (2012) 0.91
The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol (2005) 0.90
Cellular plasticity of trans- and dedifferentiation markers in human hepatoma cells in vitro and in vivo. Int J Oncol (2009) 0.89
Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines. Exp Cell Res (2012) 0.89
Overexpression of MMP9 and tissue factor in unstable carotid plaques associated with Chlamydia pneumoniae, inflammation, and apoptosis. Ann Vasc Surg (2005) 0.89
Cannabinoid receptor type I modulates alcohol-induced liver fibrosis. Mol Med (2011) 0.89
The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. Int J Oncol (2007) 0.88
Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines. BMC Cancer (2012) 0.88
The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice. Int J Oncol (2008) 0.87
Requirement of multiple phage displayed peptide libraries for optimal mapping of a conformational antibody epitope on CCR5. J Immunol Methods (2005) 0.87
Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep (2012) 0.87
The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines. Oncol Rep (2008) 0.86
Inhibition of HIV-1 by a peptide ligand of the genomic RNA packaging signal Psi. ChemMedChem (2008) 0.86
Software-based quantification of contrast-enhanced ultrasound in focal liver lesions--a feasibility study. Eur J Radiol (2009) 0.86
Detection of Chlamydia pneumoniae but not of Helicobacter pylori in symptomatic atherosclerotic carotids associated with enhanced serum antibodies, inflammation and apoptosis rate. Atherosclerosis (2003) 0.85
Differential regulation of connective tissue growth factor in renal cells by histone deacetylase inhibitors. J Cell Mol Med (2009) 0.85
Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition. Int J Oncol (2012) 0.85
Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. Int J Oncol (2012) 0.85
Influence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cells. Int J Biol Sci (2011) 0.85
Endoplasmic reticulum stress plays a pivotal role in cell death mediated by the pan-deacetylase inhibitor panobinostat in human hepatocellular cancer cells. Transl Oncol (2013) 0.85
The pan-deacetylase inhibitor panobinostat modulates the expression of epithelial-mesenchymal transition markers in hepatocellular carcinoma models. Oncol Lett (2012) 0.85
Combination of systemic thioacetamide (TAA) injections and ethanol feeding accelerates hepatic fibrosis in C3H/He mice and is associated with intrahepatic up regulation of MMP-2, VEGF and ICAM-1. J Hepatol (2006) 0.84
Different capabilities of morphological pattern formation and its association with the expression of differentiation markers in a xenograft model of human pancreatic cancer cell lines. Pancreatology (2005) 0.84
AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors. Int J Oncol (2011) 0.84
Influence of stress and health-behaviour on miRNA expression. Mol Med Rep (2011) 0.83
Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo. Int J Oncol (2007) 0.83
Percutaneous radiofrequency ablation of liver tumors using multiple saline-perfused electrodes. J Vasc Interv Radiol (2007) 0.83
Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"? J Biomed Biotechnol (2011) 0.83
Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy. World J Gastroenterol (2005) 0.83
Can quantitative tests of liver function discriminate between different etiologies of liver cirrhosis? Dig Dis Sci (2002) 0.82
Uptake and phototoxicity of meso-tetrahydroxyphenyl chlorine are highly variable in human biliary tract cancer cell lines and correlate with markers of differentiation and proliferation. Photochem Photobiol Sci (2010) 0.82
DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditions. Apoptosis (2012) 0.82
Association of stem cell marker expression pattern and survival in human biliary tract cancer. Int J Oncol (2012) 0.82
The role of sphingosine kinase isoforms and receptors S1P1, S1P2, S1P3, and S1P5 in primary, secondary, and recurrent glioblastomas. Tumour Biol (2014) 0.81
Epidermal growth factor-induced modulation of cytokeratin expression levels influences the morphological phenotype of head and neck squamous cell carcinoma cells. Cell Tissue Res (2012) 0.81
A quadruple therapy synergistically blocks proliferation and promotes apoptosis of hepatoma cells. Oncol Rep (2004) 0.81
Activation of tumor-specific T lymphocytes after laser-induced thermotherapy in patients with colorectal liver metastases. Cancer Immunol Immunother (2009) 0.81
Integrin-mediated control of cell growth. Hepatology (2003) 0.80
Early to Phase II drugs currently under investigation for the treatment of liver fibrosis. Expert Opin Investig Drugs (2014) 0.80
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma. Cancer Med (2013) 0.80
Inducibility of microsomal liver function may differentiate cirrhotic patients with maintained compared with severely compromised liver reserve. J Gastroenterol Hepatol (2003) 0.80
Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT. Int J Oncol (2011) 0.80
Biomarkers for novel targeted therapies of hepatocellular carcinoma. Histol Histopathol (2009) 0.80
Differential diagnostic challenge of chronic neutrophilic leukemia in a patient with prolonged leukocytosis. J Hematop (2008) 0.80
The combination of tamoxifen and 9cis retinoic acid exerts overadditive anti-tumoral efficacy in rat hepatocellular carcinoma. J Hepatol (2004) 0.80
Role of cannabinoid receptors and RAGE in inflammatory bowel disease. Histol Histopathol (2011) 0.79
Ru(η6-arene) complexes of combretastatin-analogous oxazoles with enhanced anti-tumoral impact. Eur J Med Chem (2010) 0.79
Gastrointestinal cancer - only a deregulation of stem cell differentiation? (Review). Int J Mol Med (2006) 0.79
Peptide mimotopes selected with HIV-1-blocking monoclonal antibodies against CCR5 represent motifs specific for HIV-1 entry. Immunol Cell Biol (2007) 0.79
Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells. Int J Oncol (2012) 0.78
Differentiation patterning of vascular smooth muscle cells (VSMC) in atherosclerosis. Virchows Arch (2009) 0.78
ARFI cut-off values and significance of standard deviation for liver fibrosis staging in patients with chronic liver disease. Ann Hepatol (2013) 0.78
Potentiated anticancer effects on hepatoma cells by the retinoid adapalene. Cancer Lett (2004) 0.77
Antitumoral efficacy of four histone deacetylase inhibitors in hepatoma in vitro and in vivo. Anticancer Res (2012) 0.77
Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma. World J Gastroenterol (2011) 0.77
Bowel Ultrasonography in the Management of Crohn's Disease. A Review with Recommendations of an International Panel of Experts. Inflamm Bowel Dis (2016) 0.77
Thymoquinone hydrazone derivatives cause cell cycle arrest in p53-competent colorectal cancer cells. Exp Ther Med (2010) 0.77
SIVmac₂₃₉-Nef down-regulates cell surface expression of CXCR4 in tumor cells and inhibits proliferation, migration and angiogenesis. Anticancer Res (2012) 0.76
Conjugates of the fungal cytotoxin illudin M with improved tumour specificity. Bioorg Med Chem (2008) 0.76
Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer. Mol Cell Biochem (2014) 0.76
Hepatic transit time of an echo enhancer: an indicator of metastatic spread to the liver. Eur J Gastroenterol Hepatol (2004) 0.76